Human Immunodeficiency Virus Type 1-Related Pulmonary Mycobacterium xenopi Infection: A Need to Treat?

Clinical Infectious Diseases

Volumn 37, Issue 9, 2003, Pages 1250-1254

  Kerbiriou, L ^a   Ustianowski, A ^b   Johnson, M A ^a   Gillespie, S H ^c   Miller, R F ^b   Lipman, M C I ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFABUTIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CLINICAL ARTICLE; COMORBIDITY; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG DISEASE; LUNG INFECTION; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MALE; MYCOBACTERIUM XENOPEI; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

EID: 0242574931     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378806     Document Type: Article

References (24)

1. Dauendorffer JN, Laurain C, Weber M, Dailloux M. Mycobacterium xenopi: epidemiological and bacteriological features [in French]. Ann Biol Clin (Paris) 2001; 59:123-30.
2. Astagneau P, Desplaces N, Vincent V, et al. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet 2001; 358:747-51.
3. Grange JM, Yates MD. Infections cause by opportunistic mycobacteria: a review. J R Soc Med 1986; 79:226-9.
4. Donnabella V, Salazar-Schicchi J, Bonk S, Hanna B, Rom WN. Increasing incidence of Mycobacterium xenopi at Bellevue hospital: An emerging pathogen or a product of improved laboratory methods? Chest 2000; 118:1365-70.
5. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunistic mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 2000; 55:210-8.
6. Kaplan JE, Masur H, Holmes KK, et al. Guidelines for preventing opportunistic infections among HIV-infected persons 2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1-52.
7. Collins CH, Grange JM, Yates MD. Mycobacteria in water. J Appl Bacteriol 1984; 57:193-211.
8. Arasteh KN, Cordes C, Ewers M, et al. HIV-related NTM infection: incidence, survival analysis and associated risk factors. Eur J Med Res 2000; 5:424-30.
9. Kolli S, Lessnau K. Mycobacterium xenopi. eMedicine Journal. 26 March 2002. Available at: http://www.emedicine.com/med/infectious_ diseases.htm. Accessed October 6, 2003.
10. Research Committee of the British Thoracic Society. First randomized trial of treatment for MAI, Mycobacterium malmoense or Mycobacterium xenopi in HIV-1 negative patients: rifampicin plus ethambutol or rifampicin plus ethambutol plus isoniazid. Thorax 2001; 56:167-72.
11. El-Solh AA, Nopper J, Abdul-Khoudoud MR, et al. Clinical and radiological manifestations of uncommon pulmonary non-tuberculous mycobacterial disease in AIDS patients. Chest 1998; 114:138-45.
12. El-Helou P, Rachlis A, Fong I, et al. Mycobacterium xenopi infection in patients with HIV-1. Clin Infect Dis 1997; 25:206-10.
13. Smith MJ, Citron KM. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax 1983; 38:373-7.
14. Jiva TM, Jacoby HM, Weymouth LA, Kaminski DA, Portmore AC. Mycobacterium xenopi: innocent bystander or emerging pathogen? Clin Infect Dis 1997; 24:226-2.
15. Simor AE, Salit IE, Velland H. The role of Mycobacterium xenopi in human disease. Am Rev Respir Dis 1984; 129:435-8.
16. Juffermans NP, Verbon A, Danner SA, Kuijper EJ, Speelman P. Mycobacterium xenopi in HIV-1-infected patients: an emerging pathogen. AIDS 1998; 12:1661-6.
17. Bachmeyer C, Blum L, Stelianides S, Benchaa B, Gruat N, Danne O. Mycobacterium xenopi pulmonary infection in an HIV-1 infected patient under HAART treatment. Sex Transm Infect 2002; 78:60-1.
18. Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP. Pulmonary infection with Mycobacterium xenopi: review of treatment and response. Thorax 1984; 39:376-82.
19. Schmit H, Schnitzler N, Riehl J, Adam G, Siebert HG, Haase G. Successful treatment of pulmonary Mycobacterium xenopi infection in a natural killer cell-deficient patient with clarithromycin, rifabutin and sparfloxacin. Clin Infect Dis 1999; 29:120-4.
20. Costrini AM, Mahler DA, Gross WM, Hawkins JE, Yesner R, D'Esopo ND. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis 1981; 123:104-9.
21. Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother 2001; 45:3229-30.
22. Parrot RG, Grosset JH. Post surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection. Tubercle 1988; 69:47-55.
23. Lang-Lazdunski L, Offredo C, Pimpec-Barthes F, Danel C, Dujon A, Riquet M. Pulmonary resection for Mycobacterium xenopi infection. Ann Thorac Surg 2001; 72:1877-82.
24. Viterbo V, Midiri M, Stellacci G, et al. Acquired immunodeficiency syndrome and pulmonary Mycobacterium xenopi infection: role of computerized tomography. Radiol Med (Torino) 2000;99:443-8 (in Italian).